Refrigerators / Freezers in Massachusetts

Boca Scientific Inc is a premier distributor of advanced biotechnology reagents, kits, and laboratory supplies for research institutions across the United States and Canada. The company curates a specialized selection of molecular biology, immunology, cell biology, and diagnostic products sourced from leading manufacturers in Europe, Asia, and the Americas. Product offerings encompass DNA polymerases, PCR reagents, cell culture media, transfection reagents, DNA/RNA purification and isolation kits, antibodies, protein markers, immunoassay optimization reagents, western blotting supplies, vector systems, freezer storage solutions, and laboratory instrumentation. Boca Scientific serves academic research labs, biotech firms, and diagnostic laboratories with high-quality consumables and equipment supporting genomics, cell biology, and molecular research workflows.

Andreas Hettich GmbH is a German manufacturer of laboratory equipment headquartered in Tuttlingen, Germany, with US operations in Beverly, MA. The company specializes in centrifuges for clinical, research, and industrial applications, including serological centrifuges for blood banks and hematology laboratories, STAT centrifuges for critical care diagnostics, and automation-ready centrifuge systems. Hettich also manufactures benchtop and specialty incubators (HettCube series) for controlled atmosphere work, low-temperature freezers (ultra-low and extra-low storage), tube strippers (manual and automatic), climate chambers, laboratory ovens, and plant growth research cabinets. The company offers factory-refurbished equipment alongside new products. All equipment is manufactured under ISO 9001, ISO 13485, and ISO 14001 certification; products are FDA registered and comply with relevant global safety standards. Hettich emphasizes German engineering quality, operational durability, low-cost maintenance, and extended service life with spare parts availability for up to 10 years post-obsolescence. The company provides localized US customer support including pre- and post-sale technical assistance, training, and field service representation.

Nexpring Health is a global MedTech company focused on Assisted Reproductive Technology (ART), formed in 2025 through the combination of Hamilton Thorne, Cook Medical's Reproductive Health business, FUJIFILM Irvine Scientific's Medical Media Business, and several other specialized fertility providers. Headquartered in Beverly, Massachusetts, the company brings together over 40 years of cumulative industry expertise to serve embryologists, clinicians, and fertility clinics worldwide. Nexpring Health offers a comprehensive end-to-end ART portfolio encompassing innovative devices, culture media, consumables, and support services designed for every stage of the IVF cycle—from pre-IVF diagnosis and sperm preparation through ovum pickup, fertilization, embryo development, embryo transfer, and cryopreservation. Key products include the Guardia™ Access Embryo Transfer Catheter family, Gynemed Specialty Media formulations, CASA systems for semen analysis, embryo culture media, cryopreservation equipment (Kryo series), incubators, aspiration needles, micromanipulation instruments, and laboratory monitoring systems. The company emphasizes streamlined workflows, product quality, and direct collaboration with ART professionals to address challenges in fertility clinic operations and improve patient outcomes.

Hemanext Inc. is a medical technology company based in Lexington, Massachusetts, specializing in advanced blood preservation and transfusion medicine solutions. The company's flagship product, Hemanext ONE®, is an FDA-authorized oxygen-controlled processing and storage system designed to preserve red blood cell (RBC) quality during refrigerated storage for up to 42 days. By removing and maintaining low oxygen levels throughout storage, Hemanext ONE® reduces oxidative storage lesions—progressive metabolic and structural damage that degrades RBC function and oxygen delivery capacity. The system preserves critical RBC parameters including membrane integrity, deformability, and metabolic stability, resulting in higher-quality blood products that maintain closer-to-physiological function. This innovation is particularly valuable for chronic transfusion patients (such as those with sickle cell disease) requiring lifelong transfusions, as well as trauma and resuscitation settings where blood quality directly impacts clinical outcomes. Hemanext operates on a consumable model facilitating seamless integration into existing hospital and blood center workflows, with CMS reimbursement recognition reflecting the clinical and economic value of oxygen-controlled RBC units.